New York lawmakers have scheduled a hearing to discuss the medical potential of psilocybin as the state considers pursuing a pathway for regulated access to the main psychedelic component of “magic mushrooms.”
In a notice published by the Assembly Health Committee on Wednesday, Chairwoman Amy Paulin (D) noted that, while psilocybin is currently listed as a Schedule I drug, the federal Food and Drug Administration (FDA) has designated it as a “breakthrough therapy” for major depression—indicating that “the therapy may offer improved results for such conditions over currently approved treatments.”
A meeting to go over the science and potential regulations of the novel therapy is scheduled for September 30. Oral testimony is by invite only from the committee, and witnesses have not yet been announced.
“Various localities have enacted measures regarding psilocybin, including the states of Colorado, Oregon, and New Mexico which allow for its supervised use, citing its potential as a treatment for some mental health conditions,” the notice says. “However, more information is needed to better understand the medicinal value that psilocybin may have as a therapy in New York State.”
“To this end, the Committee seeks to hear from researchers, medical experts, and other stakeholders on the
Read full article on Marijuana Moment
